Tax Systems Acquires Loctax to Further Strengthen Its Position in the European Tax SaaS Market
8.10.2025 10:00:00 CEST | Business Wire | Press Release
Tax Systems, a global tax and accounting software provider, has today announced the acquisition of Loctax, a leading provider of collaborative tax, compliance, risk and governance solutions for in-house global tax teams. The acquisition will enable Tax Systems to deliver on its goal of becoming EMEA’s leading SaaS tax compliance platform and will significantly accelerate the development of its product roadmap.
Loctax is the first-ever AI tax control centre that helps finance and tax teams automate compliance processes, manage risks and centralise data across all jurisdictions and tax types. Loctax brings together everything from monitoring filings and deadlines to workflows, business support and reporting, powered by AI agents that reduce manual effort.
By bringing Loctax into its portfolio, Tax Systems adds a category-defining solution that delivers the first context-aware, integrated workflow across multiple tax processes. In addition, Loctax has already embedded agentic AI in real-world use cases, complementing the existing Tax Systems products to create a powerful end-to-end platform that provides tax teams with greater oversight, automation, and assurance.
Leveraging the latest innovations in cloud and AI, the integration of the two companies’ solutions represents a significant milestone in Tax Systems’ commitment to its vision of 'one platform, total control'. For customers, the acquisition will deliver enhanced control over their tax operations. In addition to compliance, they can gain complete visibility of their data and obligations, with the confidence that all aspects of their tax function are connected and securely managed.
“This acquisition is an exciting milestone for Tax Systems,” said Bruce Martin, CEO of Tax Systems. “Loctax has created the first true tax control centre, and integrating it with our existing solutions will allow us to deliver a more comprehensive platform for tax teams. It will also significantly strengthen our market position, enabling our customers to manage their tax obligations with confidence and the advanced capabilities required. We look forward to working closely with the Loctax team.”
“Joining forces with the Tax Systems team felt like a logical next step for Loctax,” said Stevi Frooninckx, CEO of Loctax. “Our AI tax control centre can now integrate with the tax engines in the Tax Systems product portfolio, to provide end-to-end visibility and control over tax jobs like Pillar Two or the tax provision process. Together we will define the tax function of the future, and empower leading tax teams to have the highest levels of preparedness for any upcoming challenges.”
Loctax will continue to operate under its own brand as “a Tax Systems company” during the transition period, ensuring continuity for customers while benefiting from the scale and backing of Tax Systems. Its go-to-market and product teams will report into Tax Systems, maintaining close engagement with existing customers. At the same time, dedicated resources have been allocated to integrate Loctax’s platform with Tax Systems’ wider suite, unlocking the full power of the combined offering.
About Tax Systems
Tax Systems, a Providence Equity Partners (“Providence”) backed business, is a global multi-tax compliance SaaS provider, with market-leading solutions across the UK, Ireland, Europe, and the UAE. Its solutions digitise tax processes and revolutionise compliance operations, enabling tax professionals to create better opportunities and generate valuable insights from their tax function while also mitigating risk. Translating complex, ever-changing tax legislation into intuitive solutions, customers can trust that their calculations will be right, first-time, every time.
Founded in 1991, Tax Systems has over 30 years’ experience and works with over 42% of the FTSE 100 and 80% of the top advisory firms in the UK and Ireland, where more than 30,000 tax professionals are trained to use their solutions, filing over 200,000 submissions every year.
About Loctax
Loctax is the first AI tax control centre for global tax operations. It gives in-house finance and tax teams one place to manage global tax obligations, monitor KPIs and orchestrate collaboration in an autonomous and secure platform that helps teams stay ahead of surprises. With Loctax, teams centrally manage workflows with clear roles and responsibilities. Legal, tax and financial data is captured and stored, leaving a guaranteed audit trail.
Built-in AI uses company-specific data with trusted tax regulatory content to give accurate answers and practical support. It classifies documents and extracts data in multiple languages and links them to the right entity and period. Agents can manage incoming emails and create tasks to execute. The result is solid compliance, stronger control and effective business support, putting tax in a strategic seat.
Founded in 2020 in Belgium and backed by Europe’s leading VCs, including Index Ventures, Seedcamp and NAP.vc, Loctax serves customers from high-growth innovators to the world’s biggest enterprises.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251003922428/en/
Contacts
Media
Touchdown PR
Taxsystems@touchdownpr.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom